Turner et al. used the PALOMA-3 study to assess palbociclib’s efficacy by CCNE1 mRNA expression, which confirmed the prognostic role of CCNE1 in metastatic cancer. This evidence concerns the gene CCNE1 and metastatic malignant neoplasm.